The BrainDrugs-Epilepsy Study: Precision Medicine Biomarkers for Treatment Response Prediction
This prospective cohort study enrolls 350 patients (200 with first seizure, 150 newly diagnosed) to identify biomarkers predicting anti-seizure medication response and comorbid psychiatric/cognitive outcomes using EEG, MRI, PET imaging, and neuropsychological testing. Patients receive standardized treatment with lamotrigine or levetiracetam with 5-year follow-up monitoring clinical response, seizure recurrence, psychiatric symptoms, and quality of life.